SLNO vs ZLAB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SLNO Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Soleno Therapeutics, Inc. Common Stock (SLNO) driven by superior Valuation, Growth & Margin, Options & Structure while ZLAB counters with relative strength in Momentum & Technical. Fundamentally, SLNO trades at 8.4x Forward P/E with 33.6% operating margin (+0.0% YoY revenue) versus ZLAB at N/M Forward P/E and -63.0% operating margin (-6.8% YoY). In options structure, SLNO sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against ZLAB sits in UNCLASSIFIED (58th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SLNO | ZLAB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.8B | $3.0B | Larger Scale | ZLAB |
| Trailing P/E Ratio Valuation | 27.5x | N/M | Lower Multiple | SLNO |
| Forward P/E Ratio Valuation | 8.4x | N/M | Lower Multiple | SLNO |
| Revenue Growth (YoY) Growth | +0.0% | -6.8% | Higher Growth | SLNO |
| Operating Margin (TTM) Profitability | 33.6% | -63.0% | Higher Margin | SLNO |
| Net Profit Margin Profitability | 33.7% | -44.9% | Higher Margin | SLNO |
| Return on Equity (ROE) Capital Efficiency | 26.4% | -30.0% | Higher ROE | SLNO |
| 52-Week Range Position Momentum | 39% ($29โ$90) | 60% ($16โ$29) | Stronger Trend | ZLAB |
| Beta / 30D Volatility Risk Regime | 1.00ฮฒ ยท 2% Vol | 1.19ฮฒ ยท 78% Vol | Lower Realized Risk | SLNO |
| Unified Institutional Score Composite Signal | 44.5 / 100 (HOLD) | 47.4 / 100 (HOLD) | Higher Composite | ZLAB |